GWM
ABCL icon

Geneos Wealth Management’s AbCellera Biologics ABCL Stock Holding History

Geneos Wealth Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,087
Closed -$107K – 1993
2022
Q2 		$107K Hold
10,087
– – 0.01% 987
2022
Q1 		$98K Sell
10,087
-200
-2% -$1.89K ﹤0.01% 1102
2021
Q4 		$147K Sell
10,287
-50
-0.5% -$759 0.01% 1007
2021
Q3 		$177K Buy
10,337
+1,997
+24% +$35.3K 0.01% 912
2021
Q2 		$170K Buy
8,340
+250
+3% +$6.89K 0.01% 918
2021
Q1 		$215K Sell
8,090
-12,620
-61% -$503K 0.01% 934
2020
Q4 		$560K Buy
+20,710
New +$947K 0.02% 512

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.7B AUM 22.47% 1-Year Est. Return